Back to Awarded Treatment Trials


Awarded Trial: 02T-137

Grant ID

02T-137

Illness

Schizophrenia

Primary Drug/Intervention

Mirtazapine

Primary Dosage

30 mg

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Cancelled

Investigator

Bertolino

Sample Size

30

Duration of Study Period for Each Subject

90 days

Outcome Measurements

PANSS, Cognitive battery

Results

Twenty-eight patients with schizophrenia were randomized to receive mirtazapine or placebo given adjunctively to olanzapine. There was a subtle benefit for the mirtazapine group on measures of negative symptoms. No differences in other symptom ratings or cognitive measures were detected.

Publication

N/A

Link

N/A

PI Name

Alessandro Bertolino

Degree

MD

Center

Clinica Psichiatrica II, Dipartimento di Scienze Neurologiche e Psichiatriche

Institution

Universita' degli Studi di Bari

Address

Piazza Giulio Cesare, 11

City or Town

Bari

State or Province

N/A

Zip or Postal Code

70124

Country

Italy

Email Address

bertolia@psichiat.uniba.it